Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Georgia EnvironmentalGeorgia Environmental
Not Confirmed
Not Confirmed
20-22 August, 2025
Not Confirmed
Not Confirmed
25-27 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Georgia EnvironmentalGeorgia Environmental
Industry Trade Show
Not Confirmed
20-22 August, 2025
Industry Trade Show
Not Confirmed
25-27 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
10 Jul 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/revolution-lines-iambics-ai-platforms-25m-drug-discovery-deal
09 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/09/3112522/0/en/Revolution-Medicines-and-Iambic-Announce-Technology-and-Research-Collaboration-Using-Iambic-s-AI-Discovery-Tools-to-Pursue-New-Drug-Candidates.html
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250626985107/en/Iambic-Taps-Lambda-for-Increased-AI-Compute-as-it-Develops-the-Next-Generation-of-Enchant-a-Breakthrough-AI-Molecular-Property-Prediction-Model-for-Drug-Discovery
10 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250610916531/en/Iambic-Named-to-CNBCs-2025-Disruptor-50-List
04 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250604655326/en/Iambic-Completes-Dose-Escalation-in-Ongoing-Phase-11B-Study-of-Lead-Program-IAM1363-a-Small-Molecule-Inhibitor-of-Wild-Type-and-Oncogenic-HER2-Mutant-Proteins
28 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250528995295/en/Iambic-Therapeutics-to-Participate-in-June-Investor-Conferences
ABOUT THIS PAGE